Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction.

Hsu CN, Lee CT, Huang LT, Tain YL.

J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):506-13. doi: 10.1177/1470320313514123. Epub 2014 May 15.

PMID:
24833625
2.

Aliskiren prevents hypertension and reduces asymmetric dimethylarginine in young spontaneously hypertensive rats.

Tain YL, Hsu CN, Lin CY, Huang LT, Lau YT.

Eur J Pharmacol. 2011 Nov 30;670(2-3):561-5. doi: 10.1016/j.ejphar.2011.09.005. Epub 2011 Sep 21.

PMID:
21946111
3.

Melatonin therapy prevents programmed hypertension and nitric oxide deficiency in offspring exposed to maternal caloric restriction.

Tain YL, Huang LT, Hsu CN, Lee CT.

Oxid Med Cell Longev. 2014;2014:283180. doi: 10.1155/2014/283180. Epub 2014 Apr 22.

4.

Effects of maternal L-citrulline supplementation on renal function and blood pressure in offspring exposed to maternal caloric restriction: the impact of nitric oxide pathway.

Tain YL, Hsieh CS, Lin IC, Chen CC, Sheen JM, Huang LT.

Nitric Oxide. 2010 Aug 1;23(1):34-41. doi: 10.1016/j.niox.2010.03.005. Epub 2010 Apr 4.

PMID:
20371384
5.
6.

Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling.

Martins-Oliveira A, Castro MM, Oliveira DM, Rizzi E, Ceron CS, Guimaraes D, Reis RI, Costa-Neto CM, Casarini DE, Ribeiro AA, Gerlach RF, Tanus-Santos JE.

Int J Cardiol. 2013 Aug 20;167(4):1199-205. doi: 10.1016/j.ijcard.2012.03.137. Epub 2012 Apr 6.

7.

AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.

Fraune C, Lange S, Krebs C, Hölzel A, Baucke J, Divac N, Schwedhelm E, Streichert T, Velden J, Garrelds IM, Danser AH, Frenay AR, van Goor H, Jankowski V, Stahl R, Nguyen G, Wenzel UO.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1037-48. doi: 10.1152/ajprenal.00672.2011. Epub 2012 Jul 11.

PMID:
22791343
8.

Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.

Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J, Kitamura K, Gomez RA, Lopez ML, Ferrario CM.

Hypertension. 2013 Feb;61(2):417-24. doi: 10.1161/HYPERTENSIONAHA.112.201889. Epub 2012 Dec 10.

9.

Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.

Rakusan D, Kujal P, Kramer HJ, Husková Z, Vanourková Z, Vernerová Z, Mrázová I, Thumová M, Cervenka L, Vanecková I.

Am J Physiol Renal Physiol. 2010 Oct;299(4):F758-66. doi: 10.1152/ajprenal.00259.2010. Epub 2010 Jul 28.

PMID:
20668096
10.

Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.

van Esch JH, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH.

J Hypertens. 2010 Oct;28(10):2145-55. doi: 10.1097/HJH.0b013e32833d01ae.

PMID:
20625318
11.

Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats.

van Esch JH, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH.

Hypertension. 2011 Apr;57(4):852-8. doi: 10.1161/HYPERTENSIONAHA.110.169060. Epub 2011 Feb 14.

12.

Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.

Koid SS, Ziogas J, Campbell DJ.

Hypertension. 2014 Apr;63(4):768-73. doi: 10.1161/HYPERTENSIONAHA.113.02902. Epub 2014 Jan 13.

13.

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators.

Circulation. 2009 Feb 3;119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214. Epub 2009 Jan 19.

14.

Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.

Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A.

Jpn Circ J. 2001 Sep;65(9):775-8.

15.

Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.

Imbalzano E, Scarpelli M, Mandraffino G, Creazzo M, Lizio G, Trapani G, Dattilo G, Dalbeni A, Tomasello C, Sardo MA, Saitta A.

J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):956-64. doi: 10.1177/1470320314530018. Epub 2014 Jul 27.

PMID:
25070350
17.
18.

N-Acetylcysteine Prevents Programmed Hypertension in Male Rat Offspring Born to Suramin-Treated Mothers.

Tain YL, Hsu CN, Lee CT, Lin YJ, Tsai CC.

Biol Reprod. 2016 Jul;95(1):8. doi: 10.1095/biolreprod.116.139766. Epub 2016 Jun 1.

PMID:
27251093
19.

[The future of renin inhibition].

Uresin AY, Baran E.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:32-8. Turkish.

20.

Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors.

St-Jacques R, Toulmond S, Auger A, Binkert C, Cromlish W, Fischli W, Harris J, Hess P, Jie Lan, Liu S, Riendeau D, Steiner B, Percival MD.

J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):133-45. doi: 10.1177/1470320310392618. Epub 2011 Mar 10.

PMID:
21393355

Supplemental Content

Support Center